Publicaciones de interés

1. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

2. Lee Sk, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.

3. Zeiser R et Blazar BR. Acute Graft-versus-Host Disease Biology, Prevention and Therapy.

4. Zeiser R et Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med 2017;377:2565-79.

1. Teshima T. JAK inhibitors: a home run for GVHD patients?

2. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK ½ blockade in graft-versus-host disease.

3. Nicholson SE, Oates AC, Harpur AG, Ziemiecki A, Wilks AF, Layton JE. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation.

4. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

5. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

1. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, et al. Ruxolitinib for the treatment of steroid-refractory acute GvHD (REACH1): a multicenter, open-label phase 2 trial.

2. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020 May 7;382(19):1800-1810.

3. Zeiser R, von Bubnoff N, Niederwieser D, Mohty M, Bozdag SC, Forcade E, et al. Ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-versus-host disease: overall response rate by baseline characteristics in the randomized Phase 3 REACH2 trial.

4. Mohty M. Ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host-disease: 6-month follow-up from the randomized, phase 3 REACH2 study. Presented at the Virtual 47th Annual Meeting of the EBMT; March 14-17, 2021; Virtual. Abstract OS8-4. Accessed October 3, 2022.

5. Von Bubnoff N, Butler JP, Wagner EM, Forcade E, Sanz Caballer J, Russo D, et al. Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study. Presented at the Virtual 62nd ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 2240.

1. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021 Jul 15;385(3):228-238.

2. Lee S, Locatelli F, Ayuk FA, Zuckerman T, Fukushima K, Vallejo Llamas JC, et al. Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT). Presented at the Virtual 63rd ASH Annual Meeting and Exposition; December 14-18, 2021. Abstract 3909.

1. Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, et al. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients.

2. Xie R, Liu Q, Han D, Chen W, Yan H, Cheng F, et al. Ruxolitinib with or without ibrutinib as an alternative first line therapy free of corticosteroids or calcineurin inhibitors in treatment of acute graft versus-host disease. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 29 to September 1, 2020. Abstract P228.

3. Zhao Y, Shi J, Luo Y, Tan Y, Yu J, Fu H, et al. Efficacy of low-dose Ruxolitinib as Savage Therapy in Heavily Pretreated Patients with Moderate/severe steroid-refractory Chronic graft-versus-host Disease. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 29 to September 1, 2020. Abstract P215.

4. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

5. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

6. Secreto C, Tonelli M, Busca A, Scaldaferri M, Della Casa C, Giaccone L, et al. Preliminary Experience with the use of Ruxolitinib, Ibrutinib or Imatinib for the Treatment of Acute or Chronic GVHD. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 29 to September 1, 2020. Abstract P227.

7. Moiseev IS, Morozova EV, Bykova TA, Paina OV, Smirnova AG, Dotsenko AA, et al. Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults. Bone Marrow Transplant. 2020 Jul;55(7):1379-1387.

8. Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.

9. Petropoulou A, Nabergoj M, Mamez AC, Morin S, Mahne E, De Ramon Ortiz C, et al. Efficacy and Toxicity of Ruxolitinib in Patients with steroid-resistant Acute and Chronic graft-versus-host Disease after Hematopoietic Cell Transplantation. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 29 to September 1, 2020. Abstract P203.

10. Uygun V, Karasu G, Daloğlu H, Öztürkmen S, Kılıç SÇ, Yalçın K, et al. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. Pediatr Blood Cancer. 2020 Apr;67(4):e28190.

11. Atesoglu EB, Dora I, Eren C, Celik S, Kusdemir G, Cekdemir D, et al. Ruxolitinib in Chronic Graft Versus Host Disease: Single Center Experience. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 29 to September 1, 2020. Abstract P255.

12. Ilhan O, Seval GC, Bozdag SC, Deveci B, Pehlivan M, Kaynar L, et al. A New Hope in the Treatment of steroid-refractory Graft Versus Host Disease (Sr-GVHD) after Allogeneic Hematopoetic Stem Cell Transplantation (AHSCT): Ruxolitinib. Presented at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation; August 29 to September 1, 2020. Abstract P195.

13. Schroeder MA, Hari PN, Blithe A, Paranagama D, Bhatt V, DiPersio JF. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. Bone Marrow Transplant. 2022 Jun;57(6):975-981.